Improving Outcomes and Healthcare Equity in the Management of Advanced Prostate Cancer

July 17, 2024

- This evenings in oncology program will be a virtual (online) event. -

Overview:

Prostate cancer is the most common type of cancer in men and the second leading cause of cancer-related  deaths in the United States, with an estimated 34,700 deaths annually.1,2 Although most patients are diagnosed with early- stage disease, 5% are diagnosed with metastatic disease, and 30-% to 40% of patients relapse after treatments of curative intent. Once prostate cancer progresses to metastatic castrate-resistant prostate cancer (mCRPC), patients face a poor prognosis and reduced overall survival. This seminar will address health inequities while highlighting the challenges, best practices and management strategies associated with optimal community-based patient care.
 

Learning Objectives:

  1. Review the latest evidence for treatment of patients in high-risk BCR and metastasis-free survival.
  2. Examine how gene mutations and predictive biomarkers impact clinical decisions.
  3. Optimize management of advanced prostate cancer care and improve outcomes.
  4. Identify and overcome health inequities in the identification, management, and outcomes of advanced prostate cancer.
  5. Outline the MOA and clinical utility of newer therapies for advanced prostate cancer

 

Target Audience:

This activity is intended for oncology nurse practitioners, physician assistants, nurses, and other healthcare providers involved in the care of cancer patients.

This Evenings in Oncology virtual program is supported by independent medical educational grants from Astellas, Sun Pharma and Janssen Biotech, Inc. and administered by Janssen Scientific Affairs, LLC. 

Presented By

                                                                  

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Course opens: 
06/06/2024
Course expires: 
08/18/2024
Event starts: 
07/17/2024 - 4:25pm PDT
Event ends: 
07/17/2024 - 5:30pm PDT
Cost:
$0.00
Add to calendar: 
Rating: 
0

This Evenings in Oncology virtual program is supported by independent medical educational grants from Astellas, Sun Pharma and Janssen Biotech, Inc. and administered by Janssen Scientific Affairs, LLC. 

Agenda

All Times Listed are for the Pacific Standard Time Zone

Wednesday, July 17, 2024

4:25pmWelcome and Introduction
» Amanda Dreher - Program Coordinator
4:30pmImproving Outcomes and Healthcare Equity in the Managment of Advanced Prostate Cancer
»  Tanya Dorff, MD - Department of Medical Oncology Research - City of Hope Duarte, CA
» Neal Shore, MD, FACS - Medical Director - Carolina Urologic Research Center, Myrtle Beach, South Carolina
5:30pmClosing Comments
» Amanda Dreher Program Coordinator
Online Virtual Event
United States

Faculty

 

Tanya Dorff, MD

Dr. Dorff is Professor of Medicine in the Department of Medical Oncology and Therapeutics Research at the City of Hope. She serves as Section Chief of the Genitourinary Cancers Program and Vice Chair of Clinical Affairs. Dr. Dorff is co-chair of the Prostate subcommittee within the SWOG genitourinary cancer committee and is leading efforts surrounding diversity, equity and inclusion for that group. She is also a member of the NCCN guidelines panel for prostate cancer.

In addition to having published over 110 publications and over 50 review articles, Dr. Dorff serves as associate editor for Prostate Cancer Prostatic Diseases and Seminars in Urologic Oncology.  Her translational research currently focuses on immunotherapy trials, including combination approaches and novel cellular therapeutics, for prostate cancer as well as targeted therapeutics.   She has been invited to speak about her research at multiple national and international meetings.

 

Neal Shore, MD, FACS

Dr. Neal Shore graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center.Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network ,Maple Tree Cancer Alliance, Alessa Therapeutics, Photocure, and the Duke Global Health Institute.

He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology. He is the Editor of Reviews in Urology and serves as an Editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Tanya Barauskas Dorff, MD discloses that she is on an advisory board for AstraZeneca, Bayer, Janssen and Sanofi. 

Neal Shore, MD, FACS discloses that he is a consultant and on an advisory board for Amgen, Astellas, AstraZeneca, Bayer, BDendreon, Ferring, Janssen.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Access to the internet is required. Built for laptop and computer screens 

Supported Browsers:

Google Chrome: Most recent stable release  for Windows, Mac OS, or Linux

Microsoft Edge: Most recent stable release for Windows


Supported Phones & Tablets:

While our platform is accessible from mobile devices (ios and android) the platform is not optimized for use on devices with small screens.

Participation on a laptop or computer web browser is highly recommended.